Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Aimmune to Participate in Three Upcoming Investor Conferences


Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:

Event: Stifel 2019 Healthcare Conference
Date: Wednesday, November 20, 2019
Presentation Time: 3:00 p.m. Eastern Time
Location: New York, NY

Event: Piper Jaffray 31st Annual Healthcare Conference
Date: Tuesday, December 3, 2019
Presentation Time: 9:30 a.m. Eastern Time
Location: New York, NY

Event: Evercore ISI 2nd Annual HealthCONx Conference
Date: Wednesday, December 4, 2019
Presentation Time: 10:35 a.m. Eastern Time
Location: Boston, MA

A live webcast of each fireside chat will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. Replays will be available following each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for potentially life-threatening food allergies. The Company's Characterized Oral Desensitization ImmunoTherapy (CODITtm) approach is intended to provide meaningful levels of protection against allergic reactions resulting from exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first, investigational, complex biologic product candidate, AR101, is being developed as a treatment to reduce the frequency and severity of adverse events following exposure to peanut. The BLA for AR101 is under review by the FDA, which granted AR101 Breakthrough Therapy Designation in 2015 for the desensitization of peanut-allergic patients 4 to 17 years of age. The European Medicines Agency (EMA) is reviewing Aimmune's Marketing Authorization Application (MAA) for AR101 which Aimmune submitted in June 2019. Aimmune initiated a randomized phase 2 clinical trial of its second investigational, complex biologic product, AR201, for the treatment of egg allergy in August 2019. For more information, please see www.aimmune.com.


These press releases may also interest you

at 22:58
One-day mobile collections for COVID-19 testing specimens are continuing this weekend and into early next week, with the University of Mississippi Medical Center, Mississippi State Department of Health, Mississippi Emergency Management Agency and...

at 22:10
CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device "Digital Therapeutics" mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical...

at 21:45
LiveShop Inc., an e-commerce platform to enable local shops to sell easily to their local buyers, has decided to offer their platform to all sellers in the U.S. and U.K. Company announcement: With social distancing and stay-at-home directives in...

at 20:05
Technavio has been monitoring the artificial intelligence (AI) in construction market and it is poised to grow by USD 1.13 billion during 2019-2023. The report offers an up-to-date analysis regarding the current market scenario, latest trends and...

at 19:30
The "Loudspeakers Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares,...

at 19:30
Trepp, a leading provider of information, analytics, and solutions to the structured finance, commercial real estate (CRE), and banking markets has released its quarterly report of bank portfolio loan performance in commercial real estate,...



News published on 15 november 2019 at 16:10 and distributed by: